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This study was undertaken to evaluate the effect of a 
cyclooxygenase inhibitor, ibuprofen, at various time 
intervals in a live Escherichiu coli model of canine sep- 
tic shock. Group I (control) animals (n = 5) received a 
LDlOO dose of 10’ live E. coli per kilogram were given 
no further treatment. Group II animals (n = 5) received 
a 10 mg/kg bolus of ibuprofen 10 min prior to bacterial 
infusion. Group III animals (n = 5) received ibuprofen 
15 min after the bacterial infusion. Statistical analysis 
revealed the following: Group II animals had signifi- 
cantly higher MABP and significantly lower levels of 
serum fluorescent products (superoxide radical activ- 
ity), plasma thromboxane B2, prostaglandin E2, and 
endotoxin levels compared to Group I animals (P < 
0.05). Plasma levels of tumor necrosis factor (TNF) and 
interleukin-6 (IL-6) were significantly elevated (P < 
0.05) from baseline in all animals (Groups I, II, and III), 
but ibuprofen treatment failed to either increase or de- 
crease these levels. This study demonstrates that ibu- 
profen treatment can significantly reverse the deleteri- 
ous hemodynamic and metabolic effects commonly seen 
in live E. coliseptic shock without depressing the endog- 
enous production of TNF or IL-6. These data support 
the hypothesis that sepsis initiates a cascade of media- 
tors with the cytokines TNF and IL-6 being proximal 
events which in turn stimulate the next level, with ibu- 
profen probably exerting its inhibitory effect distal to 
this point in the cascade. o 1992 Academic press, IN. 
of vasoactive properties, have been demonstrated to be 
elevated in experimental models of endotoxin shock [4- 
151. In addition, several investigators have suggested 
that toxic oxygen metabolites and peroxides are formed 
during arachidonic acid metabolism [ 16-191. Recent at- 
tention has focused on the role of the cytokine tumor 
necrosis factor (TNF) in septic shock [20,21]. Levels of 
TNF are elevated during septic episodes, and elevated 
serum levels are predictive of fatal outcome [22]. Fur- 
thermore, TNF can directly stimulate neutrophils [23] 
and arachidonic acid metabolism [24, 251. 
Ibuprofen, a nonsteroidal, anti-inflammatory agent, 
which inhibits cyclooxygenase, has been shown to have 
beneficial effects in hemorrhagic and endotoxin shock 
by stabilizing blood pressure, preventing acidosis, and 
increasing survival [4, 5, 26-291. It has been demon- 
strated that administration of cyclooxygenase inhibitors 
such as aspirin, indomethacin, or ibuprofen eliminates 
the increase in plasma levels of arachidonic acid deriva- 
tives seen in shock and improves survival [27, 30,311. 
The precise biochemical mechanisms involved in 
these protective effects of ibuprofen are likely multifac- 
torial, involving both interference with oxidant injury 
and inhibition of arachidonic acid metabolite formation, 
This study was designed to document the metabolic and 
hemodynamic efficacy of ibuprofen treatment instituted 
both pre- and postlive Escherichia coli administration in 
young mongrel puppies and to investigate the role of 
tumor necrosis factor as a mediator in septic shock. 
INTRODUCTION 
MATERIALS AND METHODS 
Gram-negative septic shock remains a major clinical 
problem with significant associated morbidity and mor- 
tality. Oxygen-derived free radicals, which are generated 
during tissue ischemia via the enzyme xanthine oxidase 
or from activated neutrophils, have been implicated as 
mediators of tissue injury via peroxidation of lipid mem- 
branes [l] in a wide variety of disease processes includ- 
ing shock [2,3]. Prostaglandins, which are derived from 
the arachidonic acid cascade and which possess a variety 
Fifteen mongrel puppies weighing between 2 and 8 kg 
were randomly divided into three experimental groups 
as follows: Group I (n = 5), E. coli infusion with no fur- 
ther treatment; Group II (n = 5), bolus intravenous in- 
jection of ibuprofen’ (10 mg/kg) 10 min prior to the bac- 
terial infusion; and Group III (n = 5), the same ibupro- 
fen dose 15 min after completion of the bacterial 
infusion. On the experimental day, each puppy received 
1 To whom reprint requests should be addressed. ’ Donated by the Upjohn Company, Kalamazoo, Michigan. 
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a 2.5 mg/kg dose of xylazine hydrochloride subcutane- 
ously, followed by 20 mg/kg of intravenous pentobarbi- 
tol. The animals were intubated and allowed to respire 
spontaneously. An orogastric tube was placed for de- 
compression of the stomach. Bilateral femoral artery 
and vein catherizations were performed for monitoring 
arterial pressure, sampling blood, and administering the 
E. coli infusion and ibuprofen. In addition, a 5 fr. Swan- 
Ganz pediatric thermal dilution catheter was introduced 
into the pulmonary artery via the right femoral vein and 
connected to a Oximetrix-3 cardiac output monitor for 
monitoring thermal dilution cardiac output during the 
course of the experiment. 
Cardiac output, mean systemic blood pressure, fluores- 
cent products of lipid peroxidation, prostaglandin E, 
(PGE,), thromboxane B, (TBX,), 3,4-pamine, epineph- 
rine, norepinephrine, TNF, interleukin-6 (IL-6), and 
endotoxin levels were measured twice during a 30-min 
equilibration period prior to infusion of bacteria. An 
LDlOO dose (10’ organisms/kg) of live E. coli (Dunwald 
strain B15:0125) in a saline suspension was then infused 
into the inferior vena cava over a lo-min period. The 
number of organisms was determined by optical density 
using a Bausch and Lomb Spectronic 88 spectrophotom- 
eter at 350 nm. The above parameters were measured 
again at 15,30,60,90,120, and 180 min following bacte- 
rial infusion. The total blood volume withdrawn was 80 
ml/animal. 
Fluorescentproducts of lipidperoxidation. Serum lev- 
els of fluorescent products of lipid peroxidation were an- 
alyzed as follows: 0.5 ml of serum was extracted with 7.0 
ml of warm (45°C) 2:l chloroform:methane, vigorously 
vortexed for 2 min, and then centrifuged for 5 min. Fol- 
lowing these steps, 5.0 ml of the lower organic layer was 
transferred to a clean test tube. Two milliliters of 0.25 N 
hydrochloric acid was then added followed by 1 min of 
vortexing and 5 min of centrifugation. The resulting up- 
per layer was then transferred to disposable cuvettes and 
subsequently read using a Perkin-Elmer LS-50 Lumi- 
nescence Spectrometer with an excitation setting of 360 
nm, slit 10 nm, emmission wavelength 430 nm, slit 20 
nm [32]. 
Tumor necrosis factor. Tumor necrosis factor bioac- 
tivity was analyzed using a highly sensitive cell line, 
WEHI 164, subclone 13 (the generous gift of Dr. Anders 
Waage, University of Trondheim, Norway). These cells 
have been shown to be able to detect TNF at a concen- 
tration of 2 pg/ml [33]. We have previously demon- 
strated that this assay was unaffected by IL-l, IL-2, IL- 
6, and that there was no synergy between interferon-y 
and TNF in this assay [34]. Briefly, samples were seri- 
ally diluted in 96-well microtiter plates. The WEHI cells 
were resuspended at 5 X lo4 cells/ml in RPM1 1640 with 
10% fetal calf serum, 2 mM L-glutamine, and 0.5 pg/ml 
actinomycin D (Calbiochem, La Jolla, CA). The cells 
were added to the plates and allowed to incubate over- 
night at 37°C. Cell lysis was detected by adding MTT- 
tetrazolium and incubating the plates an additional 4 hr. 
The dark purple tetrazolium salts were then dissolved in 
acidified isopropanol. Units of TNF were calculated 
based on a recombinant standard run in the same assay. 
Catecholamines. Norepinephrine, epinephrine, and 
dopamine were measured by high pressure liquid chro- 
matography (HPLC) with electrochemical detection. An 
internal standard (1250 pg/ml dihyroxybenzylamine) 
was added to each plasma sample. The catecholamines 
were extracted from the plasma by adsorption to alu- 
mina at neutral pH and subsequently eluted with 0.1 M 
perchloric acid. The catecholamines were then eluted 
with aqueous acetonitrile/chloroacetic acid/sodium oc- 
tyl sulfate (5%/0.1 M/300 mg/liter) by reversed phase 
HPLC on a heated (35°C) C-18 column (0.5 u Biophase, 
25 X 0.4 cm, Bioanalytical Systems, West Lafayette, 
IN). They were detected amperometrically with a glassy 
carbon electrode (LC-4B, Bioanalytical Systems) at 0.65 
V. The concentration of each catechol was measured by 
comparison of the resultant peak heights with those pro- 
duced by the pure catecholamines and corrected for re- 
covery by reference to the internal standard [35]. 
Prostaglandin E2. C-18 Sep-Pak cartridges (Waters 
Associates, Milford, MA) were prewashed with 5.0 ml of 
methanol followed by 5.0 ml of deionized water. A l.O-ml 
plasma sample, to which [3H]thromboxane B, (0.01 PCi; 
NET-603, New England Nuclear, Boston, MA) was 
added, was then applied to a C-18 Sep-Pak cartridge. 
The cartridge was then washed with 20% methanol (5.0 
ml) followed by deionized water (5.0 ml). The prostaglan- 
dins were subsequently eluted by two sequential l.O-ml 
washes with 80% methanol. The solvent was evaporated 
from the extract under a stream of dry air at ambient 
temperature and the residue dissolved in 0.1 M phos- 
phate-buffered saline containing 0.1% pigskin gel (pH 
7.4) (PBS-Gel) prior to radioimmunoassay analysis. The 
recovery of [3H]thromboxane B,, monitored by counting 
a loo-p1 aliquot of the reconstituted sample, averages 
89.6 + 4.5 (SD)%. Levels of prostaglandin E, ( [3H]PgE,) 
were then measured by radioimmunoassay using com- 
mercially available antibody (Catalog Number 114010, 
Cayman Chemical Co., Ann Arbor, MI) and [3H]PgE, 
tracer (NET-428, New England Nuclear). The tracer, 
test sample, antibody, and 400 ~1 PBS-Gel were incu- 
bated for 18 hr at 4°C. The unbound prostaglandin was 
subsequently absorbed by addition of 1.0 ml of a suspen- 
sion consisting of 0.25% activated charcoal (Norit A, 
Sigma Chemical Co., Kansas City, MO) and 0.025% 
Dextran T70 (Pharmacia Fine Chemicals, Uppsala, 
Sweden) in 0.1 M phosphate-buffered saline (PBS), pH 
7.4. The supernatant was then mixed with 5.0 ml of scin- 
tillation fluid (Ecolume, ICN Biochemicals, Irvine, CA). 
The P-radioactivity due to antibody-bound tracer was 
measured in a liquid scintillation counter (Model 6893, 
Tm Analytic, Elk Grove Village, IL). The concentration 
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FIG. 1. The cardiac output is expressed as a percentage of the 
baseline. Each value is the mean of five animals. Although pretreat- 
ment with ibuprofen improved cardiac output, this was not signifi- 
cant. 
of PgE, in each sample was determined using a four-par- 
ameter logistic curve fit option of an MS-DOS program 
(Arbor Immunalysis, Ann Arbor, MI) on a Zenith Z-158 
PC (Zenith Data Systems, St. Joseph, MI). This assay 
has a sensitivity of 60 pg/ml and an interassay coeffi- 
cient of variation of 14% [36]. 
Thromboxane B2. Thromboxane B, was measured 
by radioimmunoassay method using commercially avail- 
able [3H]thromboxane B, ( [3H]TxB2) tracer (NET-603, 
New England Nuclear, Boston, MA), antibody (Fitzpa- 
trick) and a procedure similar to that used for measure- 
ment of PgE,. The thromboxane B, assay has a sensitiv- 
ity of 18 pg/ml and an interassay coefficient of variation 
of 9% [37]. 
Endotoxin assay. Endotoxin levels were measured by 
using the Limulus Amebocyte Lysate Test (Whittaker 
Bioproducts, Inc.). The plasma samples were diluted 
1:lO with pyrogen-free water, then heated to 75°C for 15 
min. Fifty microliters of sample or standard was placed 
in standard microtiter ELISA plates. Following a fif- 
teen-min incubation at 37°C 50 ~1 of limulus amebocyte 
lysate was added to each well, followed by an additional 
30-min incubation. One hundred microliters of chromo- 
genic substrate solution was added to each well, incu- 
bated for 6 min, and the reaction stopped by the addition 
of 50 ~1 of 25% acetic acid. The microtiter plates were 
then analyzed at 405 nm with a Bio-Tek EL-312 Bio- 
Kinetics Reader (Winooski, VT). 
Interleukin-6 assay. The IL-6 assay was performed 
using the B9 cell line, which is very sensitive to IL-6. 
This assay was performed by placing serial dilutions of 
the samples into 96-well microtiter plates and then add- 
25 mM Hepes, 1% pen/strep, 5 X 10e5 M mercaptoeth- 
anol, and 10% fetal calf serum. The cells were incubated 
for 68 hr at 37°C and pulsed for the final 6 hr with MTT- 
tetrazolium. The crystals were dissolved with actified 
isopropanol, and the units were calculated based upon a 
standard curve run in the same assay [38]. 
Data were subjected to statistical analyses as follows: 
Group I (control, n = 5), Group II (pre-ibuprofen-treated 
animals, n = 5), and Group III (postbacterial infusion 
ibuprofen-treated animals, n = 5), Figs. l-8. The Michi- 
gan Interactive Data Analysis System (MIDAS) was 
used to analyze data by univariate and repeated mea- 
sures analysis of variance, with P values less than 0.05 
considered significant. 
RESULTS 
Mean cardiac output. Mean cardiac outputs, ex- 
pressed as a percentage of baseline levels, are shown in 
Fig. 1. In Group I (control animals) mean cardiac output 
dropped to below 60% of baseline levels and continued to 
decrease throughout the study period. In contrast, in 
Group II (prebacteria ibuprofen-treated animals), mean 
cardiac output dropped to 50% of baseline levels by 60 
min postbacterial infusion and then continued to rise to 
approximately 70% of baseline. In Group III (postbac- 
teria ibuprofen-treated animals), mean cardiac output 
dropped significantly after the bacterial infusion, fol- 
lowed by a gradual increase after administration of the 
ibuprofen; however, these increases were not statisti- 
cally significant. 
Mean arterial pressure. Mean systemic arterial 
blood pressure, expressed as a percentage of baseline lev- 
els, is depicted in Fig. 2. In the Group I (control) ani- 
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FIG. 2. The mean arterial blood pressure is expressed as a per- 
centage of the baseline. Each value is the mean of five animals. Pre- 
ing 5000 B9 cells in RPM1 1640 with 2 mM L-glutamine, treatment with ibuprofen prevented the drop in blood pressure. 
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FIG. 3. The plasma levels of PGE2 represent the mean values of 
five animals. Pretreatment with ibuprofen prevented the rise in 
plasma PGE, . 
course of the experiment. The mean arterial pressure in 
the Group II (pretreated) animals was significantly 
higher than in the control animals, remaining at about 
90% of baseline levels throughout the study period. In 
the Group III (post-treated) animals, mean arterial 
pressure decreased to 50% of baseline following the bac- 
terial infusion and then gradually rose to about 70% of 
initial levels following the administration of the ibu- 
profen. 
Prostughndin. Mean blood prostaglandin E, (PGE,) 
levels are shown in Fig. 3, The Group II (pretreated) 
animals experienced significantly decreased levels of 
PGE, in comparison with either the Group I (control) or 
Group III (post-treated) animals, consistent with its po- 
tent activity as a cyclooxygenase inhibitor. 
Thromboxune. Mean blood Thromboxane B, (TBXJ 
levels are shown in Fig. 4. The Group II (pretreated) 
animals have significantly decreased levels of TBX, 
compared with the Group I (control) animals. Mean 
blood Thromboxane B, levels in the Group III (post- 
treated) animals were intermediate between the Group I 
and Group II dogs. 
Fluorescent products. Serum levels of fluorescent 
products of lipid peroxidation were significantly lower in 
both the pretreated (Group II) and the posttreated 
(Group III) dogs in comparison with the control (Group 
I) animals (Fig. 5). 
CatechoZamines. Plasma catecholamine levels (epi- 
nephrine, norepinephrine, and dopamine) are depicted 
in Table 1. Mean plasma catecholamine levels began to 
increase significantly 90 min following the E. coli infu- 
sion in all three experimental groups. There were no sig- 
nificant between-group differences in mean catechol- 
amine levels during the experiment. 
8000 -, 
” r ~~. -1 ~. 
-50 0 5’0 Ii0 1;0 2 
TIME (minutes) 
0 
FIG. 4. The plasma levels of TXB, represent the mean values of 
five animals. Pretreatment with ibuprofen prevented the rise in 
plasma TXB,. 
Interleukin-6. Mean plasma levels of interleukin-6 
increased significantly from baseline levels 90 min after 
the bacterial infusion; however, there are no significant 
between-group differences (Fig. 6). Neither prior or 
post-treatment with ibuprofen altered the rise in IL-6. 
Tumor necrosis factor. Mean levels of tumor necrosis 
factor increased significantly from baseline 60 minutes 
after the bacterial infusion and peaked at 2-3 hr in all 
three groups. There were no significant between-group 
differences (Fig. 7) Ibuprofen treatment appeared to 
prevent the characteristic rapid decline in plasma TNF. 
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FIG. 5. The plasma levels of fluorescent products represent the 
mean values of five animals. Pretreatment or post-treatment with ibu- 
profen prevented the rise in plasma fluorescent products. 
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TABLE 1 
Mean Plasma Catecholamine Levels (Epinephrine, 
Norepinephrine, and Dopamine) during Live E. coli 
Septic Shock in Dogs 
Time 
Control Pre-ibupr Post-ibupr 
(1) (11) (III) 
Epinephrine 
0 82 89 15 
15 251 133 476 
30 1468 245 884 
60 2713 412 2657 
90 14608 6086 28120 
120 24819 10927 34475 
180 21755 31569 58380 
Norepinephrine 
0 479 303 517 
15 358 355 600 
30 733 370 696 
60 846 863 1276 
90 5778 2064 4523 
120 7710 9809 13750 
180 9815 18575 35476 
Dopamine 
0 13 13 15 
15 13 20 14 
30 21 13 14 
60 26 40 18 
90 54 11 15 
120 164 61 60 
180 173 112 224 
En&toxin. Mean plasma levels of endotoxin are 
shown in Fig. 8. The Group II (pretreated) animals expe- 
rienced significantly decreased levels of endotoxin in 
comparison with the Group I (control) animals. 
DISCUSSION 
Several experimental models of septic shock have 
been used to demonstrate an increase in the circulating 
levels of the end products of the cyclooxygenase path- 
way, including PGE, [6,39] and TBX, [40]. Given their 
documented increase during episodes of sepsis, it is rea- 
sonable to test the hypothesis that the formation of 
these potent metabolites may be playing a critical role in 
the pathogenesis of septic shock. Indeed, previous inves- 
tigators have also shown that the cyclooxygenase inhibi- 
tor, ibuprofen, offers protection against the deleterious 
hemodynamic effects of septic shock [5,7, 281. Our data 
confirm these previous reports and show that ibuprofen 
will significantly improve hemodynamic function in ani- 
mals given a lethal bacterial challenge of E. coli. Both 
cardiac output and mean arterial blood pressure were 
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FIG. 6. The plasma IL-6 levels represent the mean values of five 
animals. IL-6 did not begin to increase until 90 min after the bacterial 
infusion. Ibuprofen treatment had no effect on the production of IL-6. 
ministration of the drug provided greater protection 
compared to giving the drug after the bacterial chal- 
lenge. Pretreatment with ibuprofen prevented the rise in 
both PGE, and TBX, induced by the septic challenge. 
Recent studies have focused attention on the role of 
endogenously produced cytokines on the altered patho- 
physiology observed in septic shock [20, 211. The link 
between the generation of tumor necrosis factor and 
septic shock is very strong, and TNF is considered piv- 
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FIG. 7. The plasma TNF levels represent the mean values of five 
animals. Levels peaked between 2-3 hr after bacterail infusion; ibu- 
profen had no significant effect over the time period studied. 
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FIG. 8. The plasma levels of endotoxin represent the mean val- 
ues of five animals. Pretreatment with ibuprofen blunted the increase 
in plasma endotoxin. 
the role of TNF come from several independent investi- 
gations. First, plasma levels of TNF are elevated in pa- 
tients in septic shock [22] or patients in intensive care 
units [41,42], and the plasma level of TNF is an indepen- 
dent predictor of outcome. Second, administration of pu- 
rified, recombinant TNF to experimental animals will 
induce organ injury [43], even when given to mice which 
are not sensitive to the effects of endotoxin [44]. Finally, 
antibodies to TNF will prevent the lethality observed in 
septic shock in response to either lipopolysaccharide 
[45], or live E. coli [46, 471. Elevated levels of interleu- 
kin-6 have also been reported in septic shock [48, 491. 
Given the pivotal role of TNF in septic shock and the 
ability of ibuprofen to block the altered pathophysiol- 
ogy, it would be tempting to speculate that TNF produc- 
tion may be inhibited. However, since in vitro studies 
have shown that PGE inhibits the production of TNF 
[25], blocking the cyclooxygenase pathway could poten- 
tially augment cytokine production. Our data indicate 
that treatment with ibuprofen has virtually no effect on 
the production of either TNF or IL-6, although there is 
slightly increased production at the 3-hr time point. 
Thus, the beneficial effects of cyclooxygenase inhibition 
are not mediated through decreased levels of TNF. 
Other investigators have shown that administration 
of purified, recombinant TNF will activate the cyclooxy- 
genase pathway in vivo. Kettlehut et al. [50] showed that 
the lethality of exogenous administered TNF could be 
blocked with ibuprofen, or indomethacin. Similarly, 
many of the pathophysiologic derangements induced 
with recombinant TNF could be blocked by ibuprofen 
[51]. The most likely explanation for these observations 
is that sepsis initiates a cascade of interactions which 
culminate in multiorgan failure and death. In this sce- 
nario, the endotoxin from the bacteria causes TNF pro- 
duction in the host. This burst of TNF activity stimu- 
lates the next wave of the cascade, including products of 
the cyclooxygenase pathway, the prostaglandins and 
thromboxanes. Therefore, although neither bacteria nor 
TNF by themselves are directly injurious, together they 
synergistically perpetuate the cascade of events which 
leads to injury and multiorgan failure [52]. Our data 
support this hypothesis, since there is no diminution in 
the levels of TNF or IL-6, while there is an improvement 
in the overall status of the animals in Groups II and III. 
The data regarding the endotoxin measurements are 
intriguing, since blocking the cyclooxygenase pathway 
apparently allowed for more efficient clearance of the 
bacteria. It is possible that inhibiting production of pros- 
taglandins, which are immunosuppressive agents, re- 
sulted in more efficient functioning of the reticuloen- 
dothelial system, so that the bacteria were cleared more 
efficiently. Further studies of this area are warranted. 
These data show that inhibition of the cyclooxygenase 
pathway results in markedly improved hemodynamics 
and a decrease in serum flourescent products during E. 
coli-induced septic shock. The improvements occured 
without any decrease in the production of TNF or IL-6 
and lends further support to the hypothesis of a cyto- 
kine-induced cascade of interactions which lead to in- 
jury during the development of septic shock. Ibuprofen 
apparently exerts its inhibitory effects at a more distal 
point in this cascade. 
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